[국가임상시험지원재단] 해외 임상시험 정보 데이터(Global Data) 보고서

Global Data Intelligence Center
구분	보고서 (영문)	업로드 날짜
제약/바이오/임상시험	Promise for Relmada Therapeutics’s Antidepressant REL-1017, But More Data Required	09-25-2023
	Generics Expected to Improve Access for Patients with Idiopathic Pulmonary Fibrosis	09-25-2023
	Are Decentralized Clinical Trials Actually Patient-Centric?	09-26-2023
	Small-Cap Companies Lead the Oncology Pipeline by Programs in Development	09-28-2023
	Could Gene Therapy Capacity Crunch Be Solved by Switch to Non-Viral Transfection?	09-29-2023
	Can Manufacturing Reforms Restore Faith in India’s Pharma Industry After Cough Syrup Scandals?	09-29-2023
	Phase III Results Boost Datopotomab Deruxtecan’s Potential in Breast Cancer	09-29-2023
	Antibody Drug Conjugates dominate with Billion-Dollar Licensing Agreements in 2022	09-29-2023
	Approval of Eisai’s Leqembi Brings First Anti-amyloid Treatment to the Japanese Market	10-02-2023
	Bio/Pharmaceutical Outsourcing Report, September 2023	10-03-2023
	Biologics Emerge as Dominating Molecule Type in Solid Tumor Indication	10-04-2023
질환별	Systemic Lupus Erythematosus and Lupus Nephritis 68-Market Analysis and Sales Forecast	09-28-2023
	Acute Myeloid Leukemia (AML): Opportunity Assessment and Forecast	09-29-2023
	Batten Disease: Competitive Landscape	09-29-2023
	Chronic Lymphocytic Leukemia: Opportunity Assessment and Forecast	09-29-2023
	Limited Innovation in the Late-Stage Pipeline for Insomnia	09-29-2023
	Early Detection Matters The Role of Mammograms in Breast Cancer Survival	10-03-2023
컨퍼런스/심포지엄 /학회	EASD 2023: Meta-Analysis Demonstrates Tirzepatide Superiority to Semaglutide	10-03-2023
	EASD 2023: Effectiveness of GLP-1 Agonists vs. DPP-4Is in Patients with T2D and CKD	10-05-2023
	EASD 2023: Efficacy of Initial Triple Combination Therapy in Drug-Naïve Patients with T2D	10-09-2023